Consequences of Changing the GOLD Reports (2007–2011–2017) on the Treatment Regimen of Patients with COPD. (4th March 2019)

• Record Type: Journal Article
• Authors: Brożek, Grzegorz Marek; Nowak, Marcin; Zejda, Jan Eugeniusz; Jankowski, Mateusz; Lawson, Joshua; Pierzchała, Władysław
• Is Part Of: COPD. Volume 16:Number 2(2019)
• Page Start: 126
• Page End: 132
• Publication Date: 2019-03-04
• Subjects: COPD -- assessment -- stratification -- Global Initiative for Chronic Obstructive Lung Disease -- pharmacotherapy -- treatment; Lungs -- Diseases, Obstructive -- Periodicals; 616.24
• DOI: 10.1080/15412555.2019.1615872
• Languages: English
• ISSNs: 1541-2555

Abstract

Abstract: Detailed treatment regimens for patients with chronic obstructive pulmonary disease (COPD) were developed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Every few years the method of classification of COPD severity and the treatment recommendations are significantly revised. The aim of this study was to determine the clinical implications of changing GOLD reports (2007–2011–2017) and the impact that these changes would have on pharmacological treatment regimens of patients with COPD. A group of 500 randomly chosen primary care physicians in Poland each provided information on 10 consecutive patients diagnosed with COPD. This data was used to simulate the therapeutic consequences of the update of the GOLD 2007 report to GOLD 2011 and GOLD 2017. Pharmacological treatment algorithms from the GOLD 2007 report prefer the use of inhaled corticosteroids (ICS) and short-acting bronchodilators (60.2% and 50%, respectively). Compared to the GOLD 2007 report, there would be an almost eightfold reduction in the frequency of short-acting bronchodilator using the GOLD 2011 report and over fourfold decrease using the GOLD 2017 report. With each subsequent update of the GOLD report, the frequency of use of ICS would be significantly ( p < 0.001) reduced. Pharmacological treatment by the GOLD 2011 and 2017 reports would be dominated by the use of long-acting bronchodilators from the group β2-agonists and muscarinic antagonist groups. Updates from the GOLD 2007 COPD report to GOLD 2011 and 2017 would have a significant impact on everyday clinical practice. Changes would result in a reduction of treatment intensity.